|
| Authors | Patients | Methods | Sample | Metabolites results |
|
| Feng et al. 2016 [7] | 59 CHD patients and 43 healthy controls
| Untargeted metabolomics method
| Plasma, urine
| GlcNAc-6-P and mannitol in CHD |
| Ahmad et al. 2016 [8] | 41 patients with end-stage heart failure | Tandem flow injection
Mass spectrometry
| Plasma | long chain acetylcarnitines in chronic heart failure |
| Oni-Orisan et al. 2016 [9] | 123 patients with coronary artery disease (CAD) versus 39 controls | Mass spectrometry | Plasma | cytochrome P450-derived epoxyeicosatrienoic acids metabolites
in CAD |
| Deidda et al. 2015 [4] | 24 heart failure patients versus 9 controls | 1H-NMR
| Plasma | 2-hydroxybutyrate, in HF patients
glycine, methylmalonate, and myoinositol in HF patients |
| Zordoky et al. 2015 [10] | 44 HF patients versus 20 controls | LC/MS 1H-NMR
| Serum | acylcarnitines, carnitine, creatinine, betaine amino acids, ketone bodies in HF patients
phosphatidylcholines, lysophosphatidylcholines, sphingomyelin in HF patients
|
| Cheng et al. 2015 [11] | 401 HF patients versus 114 controls | Mass spectrometry
| Plasma | phosphatidylcholines, arginine
ornithine, spermidine, spermine phenylalanine, tyrosine |
| Würtz et al. 2015 [12] | 1373 cardiovascular events | Quantitative nuclear magnetic resonance | Serum | phenylalanine, monounsaturated fatty acids in cardiovascular events
omega 6 fatty acids, docosahexaenoic acids in cardiovascular events |
| Zhong et al. 2014 [13] | 157 hypertension patients versus 99 controls | 1H-NMR | Serum | VLDL, LDL, lactic acid, acetone
valine, alanine, pyroacemic acid, inose, p-hydroxyphenylalanine, methylhistidine in hypertension patients |
| Vaarhorst et al. 2014 [14] | 79 cases of coronary heart disease | 1H-NMR | Plasma and serum | ornithine, TMAO
valine, arginine, creatinine |
| Shi et al. 2014 [15] | 45 cases of coronary heart disease versus 15 controls | 1H-NMR | Plasma | leucine, N-acetyl glycoprotein, α-glucose, β-glucose, phenylalanine, acetone, HDL, glutamate, glutamine, methylalanine, lysine, tyrosine, ornithine, taurine, proline, lactic acid, tryptophan, valine, acetyl-glutamic acid
β-hydroxy-isobutyric acid |
| Rizza et al. 2014 [16] | 17 major cardiovascular events (MACE) patients versus 50 controls | Mass spectrometry | Serum | medium and long chain acylcarnitines in MACE patients |
Kalim et al.
2013 [17] | 100 individuals dead of a cardiovascular cause versus 100 controls
| Liquid chromatography/mass spectrometry | Plasma | oleoyl carnitine in CV patients |
| Tenori et al. 2013 [18] | 185 heart failure patients versus 111 controls | 1H-NMR | Serum, urine | phenylalanine, tyrosine, isoleucine, creatine, TMAO, lipid, formate, lipoprotein, hypoxanthine, proline, urea, dimethylamine, serine, acetate, methanol
valine, choline, arginine, creatinine, dimethylsulfone, Gln+ Gli, alanine, l-dopa, dimethylglycine, citrate, lactate, lysine, uridine, methionine |
| Desmoulin et al. 2013 [19] | 126 acute heart failure (AHF) patients | 1H-NMR | Plasma | lactate +
low cholesterol =
short term mortality
|
| Samara et al. 2013 [20] | 25 acute decompensated heart failure (ADHF) patients versus 16 controls
| Selected ion flow tube mass spectrometry | Breath | acetone, pentane in ADHF
|
| Magnusson et al. 2013 [21] | 253 cardiovascular disease patients (CVD) versus 253 controls | Liquid chromatography/mass spectrometry | Plasma | branched and aromatic amino acids in CVD |
| Bodi et al. 2012 [22] | 20 angioplasty induced myocardial ischemia versus 9 controls | 1H-NMR | Serum | phosphoethanolamine, lactate, glucose, tyrosine, phenylalanine, glycerol in AIMI |
| Kang et al. 2011 [23] | 15 heart failure patients versus 20 controls | 1H-NMR | Urine | acetate, acetone, methylmalonic acid, cytosine, phenylacetylglycine
1-methylnicotinamide |
|
